The results of 6 months to 8 years of treatment of pituitary dwarfism in 1,959 patients in Japan were summarized.
It has been well recognized that human growth hormone (hGH) is effective in the treatment of pituitary dwarfism (Tanner et al., 1971) . We used hGH in two patients with pituitary dwarfism, observed good effects as early as 1962 (Okinaka and Shizume, 1962) and reported the additional results on 11 other patients in 1974 (Shizume et al., 1974 Doses of hGH, frequency of injection and duration of treatment Doses of hGH varied from 0.09 to 0.80 U/ kg body weight (BW) per week. However , it was 0.30 U/kg BW per week in average. These doses were divided and injected intramuscularly two or three times per week. Sometimes the same patient received injections twice a week on some occasions and three times on others . Therefore it was not possible to divide the patients into two groups ; one receiving injections consistently twice a week and another one receiving them consistently three times a week . The treatment was continued until male patients reached to 155.0 cm and female patients reached to 150.0 cm. The discontinuance of treatment was because of the shortage of hGH preparations in Japan. Even below these heights, when no significant increase of height was observed the treatment was discontinued.
In some patients , treatment was discontinued due to other various 
Discussion
This study covers almost all the patients in Japan who have been treated with hGH continously for more than 6 months. As the data are based upon the reports of many physicians all over Japan who have treated their own patients, some inaccuracy is inevitable.
Because of the shortage of hGH in Japan, the doses used in these patients were relatively lower than those in American and European reports. However, the summarized data on these large numbers of patients confirmed the following observations previously reported by several other (Frasier et al., 1977) . 1) 0.1 U/kg BW/week produces a good response even though it is not optimal. The effect increases with increasing dose, but not proportionally to the increase in dose. 2) Young and immature children show better responses. 3) There are very few side effects. However, impairment of capital femoral epiphysis was observed in a few cases. It is well known that hypothyroidism develops in some cases of pituitary dwarfism during hGH treatment. According to the above data, 559 of the patients received thyroid hormone during hGH treatment. However from the data obtained, it is impossible to determine how many of the patients were administered thyroid hormone at the time of the initiation of growth hormone treatment or in how many cases hypothyroidism developed later during hGH treatment.
It is regrettable that this incidence cannot be calculated from this study.
